Judah Folkman American cytologist, oncologist. Date of Birth: 24.01.1933 Country: USA

1. American cytologist and oncologist
2. Education and Early Career
3. Contributions to Oncology
4. Recognition and Later Life

American cytologist and oncologist

Judah Folkman was an American cytologist and oncologist, known for his work on the theory of angiogenesis in tumor growth. His research in the 1990s led to the development of a new generation of anti-cancer drugs. Folkman's work gave rise to the field of angiogenesis research, based on the premise that restricting the blood supply to tumors can slow their growth.

Education and Early Career

Born into a rabbi's family, Folkman received his education at Ohio State University (1953) and Harvard Medical School (1957), where he spent most of his life. Even as a student, he gained recognition in the scientific community as a co-author of studies on liver cancer surgery and cardiac pacemakers. In the 1960s, he served as a surgeon at a civilian hospital in Massachusetts and at a military hospital near Washington, D.C. It was during his military service that he developed a new type of long-acting implantable drug delivery system, which led to the release of the Norplant contraceptive implant and other similar products. He also began studying the relationship between tumor growth and blood circulation during this time.

Contributions to Oncology

In 1967, Folkman became the chief oncology surgeon at the Boston Children's Hospital affiliated with Harvard Medical School. In 1971, he first published his theory in the New England Journal of Medicine, though it took a decade for the scientific community to fully recognize its significance. Continuing his practical experiments, his laboratory identified the first angiogenesis inhibitors and initiated clinical trials with these drugs. From the 1980s to the 2000s, Folkman continued his applied research at Harvard and the Boston Children's Hospital, where he led the Vascular Biology Department. Throughout his life, he published around 400 articles in peer-reviewed medical journals and numerous monographs.

Recognition and Later Life

In 1992, Folkman received the Wolf Prize for his work on angiogenesis, and public recognition came to him in 1998 when the latest anti-cancer drugs, such as Avastin, were being prepared for clinical trials. The scientific community remains divided on the mechanisms of action of such drugs, but the majority supports Folkman's hypothesis. In the last decade of his life, Folkman focused on studying the course of oncological diseases in individuals with Down syndrome. Statistically, people with Down syndrome are significantly less likely to develop cancer compared to intellectually typical individuals. Folkman hypothesized that there are genetic factors responsible for suppressing tumor growth in individuals with Down syndrome, which could be identified and utilized for the benefit of all people. However, these studies remained unfinished. On January 14, 2008, Folkman passed away suddenly in the waiting area of an airport in Denver.